- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04963946
STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (STAIR)
The irreversible Bruton's Tyrosine Kinase (BTK) inhibitor acalabrutinib (ACA) has potent clinical activity as a single agent in patients with treatment naive and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
However, a growing body of concerns is raising regarding the unlimited administration of targeted therapy as BTKi. First, long-term treatments expose the patients to increased risk of specific adverse events (infections, bleeding events or cardiovascular problems). Second, continuous administration might also increase the risk of clonal evolution and therapeutic resistance resulting from genetic alterations such as BTK or PLCG2 mutations. Discontinuation of therapy after a fixed period is expected to prevent these events.
Rapid and deep responses yielded by ACA in elderly patients pave the way of investigating a limited 18-months period schedule. This study aims to investigate the 1-year PFS upon ACA discontinuation and efficacy of restarting ACA upon symptomatic relapse.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This multicenter, non comparative, randomized phase II trial aims at evaluating the impact of a stopping ACA strategy on PFS of CLL patients >70 years or with coexisting comorbidities.
Patients will receive continuous Acalabrutinib (ACA) at 100 mg bid for 18 months. Dose adaptations will be made according to labels.
In case of first occurrence of grade ≥3 non-hematological toxicity, febrile grade ≥3 neutropenia or grade ≥4 hematological toxicity treatment must be stopped until recovering grade 1 or baseline state.
- 1st and second occurrence : restart at 100 mg twice daily
- 3rd occurrence : restart at 100 mg once daily
- 4th occurrence : discontinue acalabrutinib
At month 19 day 1, patients will be randomized (1:2) in two arms:
- Arm 1 = Control arm (acalabrutinib) continuing acalabrutinib until disease progression or unacceptable toxicity or
- Arm 2 = Experimental arm (watch and monitor) without ACA (see trial design).
Upon progression in the experimental arm, all patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria.
Upon progression in the control arm, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria.
Patients will be monitored every three months until M31 then every 6 months until M60 or progression for both response and toxicity according to CTCAE v.5.
Minimal/Measurable Residual Disease (MRD) assessment will be done at month 19 day 1 in the peripheral blood.
CT-scan will be performed at baseline, then at month 19 day 1 and every 6 months within the year after randomization.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Delphine NOLLET
- Phone Number: +33 218370609
- Email: d.nollet@chu-tours.fr
Study Contact Backup
- Name: Valérie ROUILLE, Pr
- Phone Number: +33 467332645
- Email: v-rouille@chu-montpellier.fr
Study Locations
-
-
-
Angers, France, 49933
- Recruiting
- Chu Angers
-
Contact:
- Aline CLAVERT, MD
- Phone Number: +33 2 41 35 45 24
- Email: aline.clavert@chu-angers.fr
-
Argenteuil, France
- Recruiting
- ARGENTEUIL - Centre hospitalier Victor Dupouy
-
Contact:
- Driss CHAOUI
-
Avignon, France, 84000
- Recruiting
- Ch Avignon
-
Contact:
- Safia CHEBREK, Dr
- Phone Number: +33 4 32 75 93 00
- Email: chebrek.safia@ch-avignon.fr
-
Bayonne, France, 64109
- Recruiting
- CH Cote Basque
-
Contact:
- Julie GAY, MD
- Phone Number: +33559443832
- Email: jgay@ch-cotebasque.fr
-
Bobigny, France
- Recruiting
- BOBIGNY - Hôpital Avicenne
-
Contact:
- Vincent LEVY, Pr
-
Cesson-Sévigné, France, 35510
- Recruiting
- Hôpital Privé Sévigné
-
Contact:
- Xavier CAHU, Dr
- Phone Number: 33 (0)2 23 21 05 50
- Email: cahu.xavier@yahoo.fr
-
Clermont-Ferrand, France, 63000
- Recruiting
- CHU Estaing - Hématologie Clinique Adulte
-
Contact:
- Romain GUIEZE, Dr
- Phone Number: +33 4 73 75 00 65
- Email: rguieze@chu-clermontferrand.fr
-
Corbeil-Essonnes, France
- Recruiting
- Corbeil-Essonnes -
-
Contact:
- Laurence SIMON, Dr
-
Grenoble, France, 388043
- Recruiting
- CHU Grenoble - Hématologie
-
Contact:
- Lysiane MOLINA, Dr
- Phone Number: 04 76 76 57 55
- Email: LMolina@chu-grenoble.fr
-
Le Mans, France, 72000
- Recruiting
- Centre Hospitalier Du Mans
-
Contact:
- Kamel LARIBI, Dr
- Phone Number: 02 43 43 43 43
- Email: klaribi@ch-lemans.fr
-
Lille, France, 59000
- Recruiting
- Hopital Saint Vincent De Paul
-
Contact:
- Bénédicte HIVERT, Dr
- Phone Number: 33 (0)3 20 87 45 32
- Email: hivert.benedicte@ghicl.net
-
Lyon, France, 69373
- Recruiting
- Centre Léon Bérard - Hématologie
-
Contact:
- Anne-Sophie MICHALLET, Dr
- Phone Number: 04 78 78 26 41
- Email: anne-sophie.michallet@lyon.unicancer.fr
-
Marseille, France, 13273
- Recruiting
- Institut Paoli-Calmettes - Hématologie Clinique
-
Contact:
- Thérèse AURRAN, Dr
- Phone Number: 04 91 22 38 68
- Email: aurrant@ipc.unicancer.fr
-
Metz, France, 57085
- Not yet recruiting
- Centre Hospitalier Regional Metz Thionville
-
Contact:
- Philippe CARASSOU, MD
- Phone Number: +333 87 55 33 63
- Email: p.carassou@chr-metz-thionville.fr
-
Montpellier, France, 34295
- Recruiting
- Hôpital Saint-Eloi - Hématologie Clinique
-
Contact:
- Emanuelle TCHERNONOG, Dr
- Phone Number: 04 67 33 24 17
- Email: e-tchernonog@chu-montpellier.fr
-
Mulhouse, France, 68100
- Recruiting
- Hopital E.Muller
-
Contact:
- Bernard DRENOU, Dr
- Phone Number: 03 89 64 77 85
- Email: drenoub@ghrmsa.fr
-
Orléans, France, 44100
- Recruiting
- CHR ORLEANS - Hématologie
-
Contact:
- Marlene OCHMANN, Dr
- Email: marlene.ochmann@chr-orleans.fr
-
Paris, France, 75651
- Recruiting
- Hopital Pitie Salpetriere Service Hematologie Clinique - Pavillon de L'Enfant Et Adolescent
-
Contact:
- Damien ROOS WEIL, Dr
- Phone Number: 01 42 16 15 96
- Email: damien.roosweil@aphp.fr
-
Perpignan, France, 66000
- Recruiting
- CENTRE HOSPITALIER SAINTJEAN - Hématologie Clinique
-
Contact:
- Laurence SANHES, Dr
- Phone Number: +33(0)4 68 61 89 02
- Email: laurence.sanhes@ch-perpignan.fr
-
Pessac, France, 33604
- Recruiting
- Bordeaux Pessac
-
Contact:
- Marie-Sarah DILHUYDY, MD
- Phone Number: +33557656511
- Email: marie-sarah.dilhuydy@chu-bordeaux.fr
-
Pierre-Bénite, France, 69495
- Recruiting
- Centre Hospitalier Lyon Sud
-
Contact:
- Emmanuelle FERRANT, MD
- Phone Number: +33478864521
- Email: emmanuel.ferrant2@chu-lyon.fr
-
Poitiers, France, 86021
- Not yet recruiting
- Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire
-
Contact:
- Cécile TOMOWIAK, Dr
- Phone Number: 05 49 44 43 07
- Email: cecile.tomowiak@chu-poitiers.fr
-
Pontoise, France
- Recruiting
- CERGY-PONTOISE - Centre Hospitalier René Dubos
-
Contact:
- Hugo Gonzalez, Dr
-
Reims, France, 51092
- Recruiting
- CHU Reims
-
Contact:
- Anne QUINQUENEL, Dr
- Phone Number: 33 (0)3 26 78 36 44
- Email: aquiquennel@chu-reims.fr
-
Rennes, France, 35033
- Recruiting
- CHU Pontchaillou - Hématologie Clinique BMT-HC
-
Contact:
- Sophie DE GUIBERT, Pr
- Phone Number: 02 99 28 42 91
- Email: sophie.de.guibert@chu-rennes.fr
-
Rouen, France, 76038
- Recruiting
- Centre Henri Becquerel - Service Hématologie Clinique
-
Contact:
- Stéphane LEPRETRE, Pr
- Phone Number: +33 2 32 08 29 46
- Email: stephane.lepretre@chb.unicancer.fr
-
Saint-Priest-en-Jarez, France, 42271
- Not yet recruiting
- Institut de Cancérologie Lucien Neuwirth
-
Contact:
- Emilie CHALAYER, Dr
- Email: emilie.chalayer@icloire.fr
-
Toulouse, France, 31059
- Recruiting
- IUCT ONCOPOLE - Hématologie
-
Contact:
- Loïc YSEBAERT, Dr
- Phone Number: 05 31 15 63 51
- Email: ysebaert.loic@iuct-oncopole.fr
-
Tours, France, 37044
- Recruiting
- Hôpital Bretonneau - Hématologie et Thérapie Cellulaire
-
Contact:
- Caroline DARTIGEAS, Dr
- Phone Number: 02 47 47 37 12
- Email: c.dartigeas@chu-tours.fr
-
Vandœuvre-lès-Nancy, France, 54500
- Recruiting
- CHU Nancy Brabois
-
Contact:
- Pierre FEUGIER, Pr
- Phone Number: 33 (0)3 83 15 32 82
- Email: p.feugier@chru-nancy.fr
-
Vannes, France
- Recruiting
- Vannes - Chba
-
Contact:
- Antoine BONNET, Dr
-
Versailles, France
- Recruiting
- VERSAILLES - Hôpital André Mignot
-
Contact:
- Fatiha MERABET, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 70 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status < 2
- Previously untreated CLL or Small Lymphocytic Lymphoma (SLL)
- CLL or SLL requiring treatment according to the iwCLL 2018 criteria2
- Total Cumulative Illness Rating Scale (CIRS) score > 6 or 30 < CrCl < 69 mL/min
- Both patients with or without TP53 disruption 17p deletion and/or TP53 mutations) can be included
- Patients can be included whatever their IGHV mutational status
- Patients with therapy-controlled cardiovascular comorbidities and/or anticoagulation (novel oral anticoagulant alone, aspirin alone, heparin alone) can be included (patients treated by vitamin K antagonist or dual anti-platelet therapy cannot be included)
- Life expectancy > 6 months
- Adequate hematology values: absolute neutrophil count ≥ 0.75 x 109/L, platelet count ≥ 50 x 109/L.
- Adequate liver function as indicated by a total bilirubin <1.5, aspartate transaminase and alanine transaminase ≤3 the institutional upper limits of normal values, unless directly attributable to CLL
- Signed (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including specify biology analysis, and are willing to participate in the study.
Exclusion Criteria:
- Known HIV seropositivity
Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
- Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
Known history of human immunodeficiency virus, serologic status reflecting active hepatitis B virus or hepatitis C virus infection, any uncontrolled active systemic infection along with subjects who are on ongoing anti-infective treatment and subjects who have received vaccination with a live attenuated vaccine within 4 weeks before the first dose of study treatment
- Subjects who are hepatitis B core antibody (anti-HBc) positive and who are hepatitis B surface antibody (anti-HBs) negative will need to have a negative hepatitis B virus Polymerase Chain Reaction (PCR) result before enrollment. Those who are hepatitis B surface antigen (HBsAg) positive or hepatitis B virus PCR positive will be excluded.
- Subjects who are hepatitis C virus antibody positive will need to have a negative hepatitis C virus PCR result before enrollment. Those who are hepatitis C virus PCR positive will be excluded
- Active and uncontrolled autoimmune cytopenia, including autoimmune hemolytic anemia (AIHA) (isolated positive Direct Antiglobulin Testing (DAT) is not an exclusion criteria) and idiopathic thrombocytopenic purpura (ITP).
- Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.
- Patients treated by vitamin K antagonist or dual anti-platelet therapy
- History of bleeding diathesis (e.g. hemophilia or von Willebrand disease)
- History of confirmed progressive multifocal leukoencephalopathy (PML).
Concurrent severe diseases which exclude the administration of therapy :
- heart insufficiency New York Heart Association (NYHA) grade III/IV, Left Ventricular Ejection Fraction (LEVF) < 50% and or Recirculation Fraction (RF) < 30%, myocardial infarction within the past 6 months prior to study
- Significant cardiovascular disease such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional (Subjects with controlled, asymptomatic atrial fibrillation are allowed to enroll on study)
- severe chronic obstructive lung disease with hypoxemia
- history of stroke or intra-cranial hemorrhage within the last 6 months
- severe diabetes mellitus
- uncontrolled hypertension
- impaired renal function with creatinine clearance < 30 ml/min according the formula of Cockcroft and Gault
- Patient who requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving proton-pump inhibitors who switch to H2-receptor antagonists or antacids are eligible for enrollment in this study.
- Disease significantly affecting gastrointestinal function (malabsorption syndrome, stomach or small bowel resection)
- Evidence for Richter syndrome
- Treatment with any of the following within 7 days prior to the first dose of study drug: steroid therapy for anti-neoplastic intent.
- A significant history of renal, neurologic, psychiatric, endocrine, metabolic, immunologic, cardiovascular, or hepatic disease that, in the opinion of the investigator, would adversely affect the patient's participation in this study or interpretation of study outcomes
- Major surgery within 30 days prior to the first dose of study treatment.
History of prior other malignancy that could affect compliance with the protocol or interpretation of results, with the exception of the following:
- curatively treated basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix at any time prior to study.
- other cancers not specified above that have been curatively treated by surgery and/or radiation therapy from which patient is disease-free for ≥ 5 years without further treatment
- Adult under law-control
- Fertile male patients who cannot or do not wish to use an effective method of contraception, during and for 12 months after the final treatment used for the purposes of the study
- No affiliation to social security
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: watch and monitor
After 18 months of acalabrutinib treatment, patients will stop acalabrutinib treatment for watch and monitor until month 60.
If progression disease, patients will be re-treated with ACA at the last received dose after central reviewing of treatment criteria.
|
discontinuation of acalabrutinib after 18 months in treatment-naïve CLL patients
|
Active Comparator: Acalabrutinib
After 18 months of acalabrutinib treatment, patients will continue acalabrutinib treatment until month 60.
If progression disease or unacceptable toxicity, patients will receive next line therapy at the discretion of their physicians and according to iwCLL 2018 criteria
|
continuation of acalabrutinib at the same dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS) at one year after acalabrutinib interruption
Time Frame: until 12 months after acalabrutinib interruption
|
Time from randomization (M19 : discontinuation of acalabrutinib after of 18 months treatment) to progression (needing therapy or not) or death from any cause
|
until 12 months after acalabrutinib interruption
|
Collaborators and Investigators
Investigators
- Principal Investigator: Loïc Ysebaert, Pr, French Innovative Leukemia Organisation
- Principal Investigator: Romain GUIEZE, Pr, French Innovative Leukemia Organisation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FILOCLL14 - STAIR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Untreated Chronic Lymphocytic Leukemia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Untreated Chronic Lymphocytic LeukemiaUnited States
-
AstraZenecaActive, not recruitingUntreated Chronic Lymphocytic LeukemiaThailand, Vietnam, Philippines, China, Taiwan
-
AstraZenecaRecruitingPreviously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)Japan
-
Chronic Lymphocytic Leukemia Research ConsortiumCelgene CorporationUnknownChronic Lymphocytic Leukemia | CLL | Untreated | First-Line | Front-line | Initial TherapyUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingVitamin D Deficiency | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Untreated Chronic Lymphocytic LeukemiaUnited States
-
University Hospital, CaenCNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, FranceCompletedUntreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma PatientsFrance
-
Gruppo Italiano Malattie EMatologiche dell'AdultoUnknownElderly Patients | Small Lymphocytic Lymphoma | CLL | B-cell | Untreated B-CLLItaly
-
National Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingLeukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Leukemia, Chronic Lymphatic | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | B-Lymphocytic Leukemia, Chronic | Leukemia, Chronic Lymphocytic, B-Cell | Lymphocytic Leukemia, Chronic, B Cell | Lymphocytic Leukemia...United States
-
National Cancer Institute (NCI)CompletedB-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedRefractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic LeukemiaUnited States
Clinical Trials on Stop ACA
-
Ignacio J. Amat SantosInstituto de Salud Carlos III; Gerencia Regional de Salud de Castilla y LeonRecruitingSevere Aortic Valve StenosisSpain
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Unknown
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingDifficult Intubation | Airway DiseaseTurkey
-
Aalborg University HospitalCompletedGraves Disease | Hyperthyroidism
-
Medtronic Spine LLCWithdrawnLumbar Spinal Stenosis
-
AGO Study GroupCompletedFallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian CancerGermany
-
Central Jutland Regional HospitalCompletedMedical PatientsDenmark
-
Universitaire Ziekenhuizen KU LeuvenCompletedPregnant Women With Type 1 DiabetesBelgium
-
Stanford UniversityUniversity of MichiganUnknownCardiomyopathy, HypertrophicUnited States
-
Insel Gruppe AG, University Hospital BernRecruiting